Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

(2014) Edward Sausville et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

(2014) R. Moser et al.   CLINICAL CANCER RESEARCH

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions

(2014) Ana Slipicevic et al.   GYNECOLOGIC ONCOLOGY

High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients

(2013) Gry Irene Magnussen et al.   BMC CANCER

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

(2013) Takashi Seto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

(2013) L. Chaudhuri et al.   HAEMATOLOGICA

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

(2013) H. E. Haarberg et al.   MOLECULAR CANCER THERAPEUTICS

Targeting p53 in melanoma

(2013) Neil F. Box et al.   Pigment Cell & Melanoma Research

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

(2012) Maria Vinci et al.   BMC BIOLOGY

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

(2012) Amy D Guertin et al.   Cancer Cell International

Surgery for Distant Melanoma Metastasis

(2012) Anna M. Leung et al.   CANCER JOURNAL

Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma

(2012) M. R. Russell et al.   CANCER RESEARCH

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?

(2012) Hidemasa Goto et al.   CANCER SCIENCE

Wee1-Hsp90 inhibitor combination treatment

(2012) Vinata B. Lokeshwar   CELL CYCLE

Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo

(2012) Laura Carrassa et al.   CELL CYCLE

Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy

(2012) Geeta Mehta et al.   JOURNAL OF CONTROLLED RELEASE

The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer

(2012) Kenny Chitcholtan et al.   Journal of Translational Medicine

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

(2012) Fritz Lai et al.   MELANOMA RESEARCH

Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

(2012) H. Beck et al.   MOLECULAR AND CELLULAR BIOLOGY

A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress

(2012) K Brooks et al.   ONCOGENE

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

(2011) Jantine PosthumaDeBoer et al.   BMC CANCER

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

(2011) Kurtis D. Davies et al.   CANCER BIOLOGY & THERAPY

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

Targeting the S and G2 checkpoint to treat cancer

(2011) Tao Chen et al.   DRUG DISCOVERY TODAY

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication

(2011) C. S. Sorensen et al.   NUCLEIC ACIDS RESEARCH

Epidemiology of Melanoma

(2011) Darrell S. Rigel   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase

(2010) Halfdan Beck et al.   JOURNAL OF CELL BIOLOGY

γH2AX: a sensitive molecular marker of DNA damage and repair

(2010) L-J Mah et al.   LEUKEMIA

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

(2010) S Zenvirt et al.   ONCOGENE

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Chk1 Is a Histone H3 Threonine 11 Kinase that Regulates DNA Damage-Induced Transcriptional Repression

(2008) Midori Shimada et al.   CELL

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS